title: Prevention of nonalcoholic steatohepatitis in rats by two manganese-salen complexes.
abstract: Nonalcoholic steatohepatitis (NASH), a progressive stage of nonalcoholic fatty liver disease (NAFLD), is characterized by steatosis with inflammation. Investigations have suggested that oxidative stress may play an important role in the progress of NAFLD to NASH. To provide further insights into beneficial effects of antioxidants in NASH prevention, we employed two manganese-superoxide dismutase/catalase mimetics, manganese N,N`-bis(salicyldene) ethylene diamine chloride (EUK-8) and manganese-3-methoxy N,N`-bis(salicyldene)ethylenediamine chloride (EUK-134), as two salen representatives and vitamin C as the standard antioxidant.
  
  
  
  Experimental NASH was induced in Male N-Mary rats by feeding a methionine/choline-deficient (MCD) diet to rats for 10 weeks. The rats (n = 5, 30 mg/kg/day) were randomly assigned to receive vitamin C, EUK-8, EUK-134 or vehicle orally.
  
  
  
  Administration of salens together with the MCD diet reduced the serum aminotransferases, glutathione transferase and alkaline phosphatase, cholesterol, and LDL contents. In addition, the EUK-8 and EUK-134 improved NASH pathological features in liver of MCD-fed rats.
  
  
  
  EUK-8 and EUK-134 supplementation reduces NASH-induced abnormalities, pointing out that antioxidant strategy could be beneficial for prevention of NASH.
authors.affiliation: Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
authors.forename: Alireza
authors.initials: A
authors.lastname: Rezazadeh
authors.affiliation: Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
authors.forename: Razieh
authors.initials: R
authors.lastname: Yazdanparast
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000627:therapeutic use; D002614:Chelating Agents / Q000627:therapeutic use*; D002794:Choline; D004032:Diet; D005029:Ethylenediamines / Q000627:therapeutic use*; D005234:Fatty Liver / Q000188:drug therapy / Q000517:prevention & control*; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008297:Male; D017895:Manganese Compounds / Q000627:therapeutic use; D008715:Methionine; D065626:Non-alcoholic Fatty Liver Disease; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats
chemical_list: D000975:Antioxidants; D002614:Chelating Agents; D005029:Ethylenediamines; D017895:Manganese Compounds; C011452:disalicylaldehyde ethylenediamine; D008715:Methionine; D002794:Choline; D001205:Ascorbic Acid
keywords: Fatty liver; Oxidative stress; Antioxidants